-
公开(公告)号：WO2021252821A1
公开(公告)日：2021-12-16
申请号：PCT/US2021/036897
申请日：2021-06-11
发明人： KELLER, Lorraine , PADIDAM, Malla
IPC分类号： A61K39/00 , A61K39/12 , A61K39/39 , A61K2039/53 , A61K2039/552 , A61K2039/572 , A61K2039/575 , A61K2039/80 , A61P35/00 , C07K14/005 , C07K14/70539 , C07K2319/00 , C07K2319/40 , C07K2319/70 , C12N2710/10343 , C12N2710/12022 , C12N2710/12034 , C12N2710/16021 , C12N2710/16622 , C12N2710/16634 , C12N2710/16722 , C12N2710/16734 , C12N2750/10022 , C12N2760/16121 , C12N2760/16122 , C12N2760/16134 , C12N2770/10022 , C12N2770/10034 , C12N2770/20021 , C12N2770/20022 , C12N2770/20034
摘要： Provided are pharmaceutical/veterinary compositions including (1) an effective amount of nucleic acid molecule(s) comprising nucleotide sequences encoding (a) disease-causing agent-associated antigen(s) and (b) innate trained immunity immunomodulator(s), and (2) an effective amount of either (a) calcium phosphate nanoparticles associated with the molecules that detectably enhance cellular uptake of the molecules, immunogenicity of the composition, or both, or (b) a nonpathogenic bacterial vector that contains the molecules and detectably promotes delivery of the nucleic acid molecules. Immunomodulators can include signal transducing activator protein sequences, antigen(s) can include immune cell targeting sequences (e.g., alphaherpesvirus glycoprotein D sequences) or internal targeting sequences (such as polyubiquitin sequences), and expression products can include checkpoint inhibitors. Provided also are methods of using compositions to treat or prevent diseases in humans or livestock/companion animals, including viral diseases and cancers.
-
公开(公告)号：WO2022234473A1
公开(公告)日：2022-11-10
申请号：PCT/IB2022/054111
申请日：2022-05-04
发明人： BAILLAT, David , MULVEY, Matthew
IPC分类号： C12N7/02 , A61K38/16 , C07K16/12 , C07K16/30 , C12N15/86 , A61K35/763 , A61P35/00 , C07K14/005 , C07K16/14 , C07K16/18 , C07K16/28 , C07K16/2803 , C07K16/3069 , C07K16/40 , C07K2317/31 , C07K2317/569 , C07K2317/622 , C07K2318/20 , C07K2319/73 , C12N2710/16622 , C12N2710/16632 , C12N2710/16645
摘要： Provided herein are bispecific adaptor proteins and their use for retargeting oncolytic HSV to target cells, such as tumor cells.
-
公开(公告)号：WO2022157155A8
公开(公告)日：2022-07-28
申请号：PCT/EP2022/051032
申请日：2022-01-18
发明人： MOLS, Johann , TOUSSAINT, Marie
IPC分类号： A61K39/245 , C07K14/035 , A61K2039/505 , A61K39/12 , C07K14/005 , C12N2710/16622 , C12N2710/16634
摘要： The present invention relates to a HSV2 Fc receptor or immunogenic fragment or variant thereof for use in generating a cross reactive immune response against HSV1 in a subject. Also provided is a HSV1 Fc receptor or immunogenic fragment or variant thereof for use in generating a cross reactive immune response against HSV2 when administered to a subject.
-
公开(公告)号：WO2022003362A1
公开(公告)日：2022-01-06
申请号：PCT/GB2021/051678
申请日：2021-07-01
发明人： ISALAN, Mark , MIELCAREK, Michal
IPC分类号： C07K14/005 , C12N15/861 , A61K38/00 , A61K48/005 , A61P25/00 , C07K14/4702 , C07K2319/02 , C07K2319/10 , C07K2319/715 , C07K2319/73 , C07K2319/81 , C12N2710/16622 , C12N2750/14143
摘要： Disclosed herein are polypeptides for use in treating diseases associated with pathogenic genomic repeat sequences, such as neurological disorders. Also disclosed are nucleic acid molecules and vectors that encode such polypeptides. Therapeutic uses and methods for treating such diseases are also disclosed; in particular, therapeutic uses and methods comprising complementary pairs and combinations of therapeutic polypeptides, nucleic acids or vectors. Also disclosed is a method and associated peptides and nucleic acids for active, long-term delivery of therapeutic molecules to target cells in vivo or in vitro.
-
公开(公告)号：WO2022157155A2
公开(公告)日：2022-07-28
申请号：PCT/EP2022/051032
申请日：2022-01-18
发明人： MOLS, Johann , TOUSSAINT, Marie
IPC分类号： A61K39/245 , C07K14/035 , A61K2039/505 , A61K39/12 , C07K14/005 , C12N2710/16622 , C12N2710/16634
摘要： The present invention relates to a HSV2 Fc receptor or immunogenic fragment or variant thereof for use in generating a cross reactive immune response against HSV1 in a subject. Also provided is a HSV1 Fc receptor or immunogenic fragment or variant thereof for use in generating a cross reactive immune response against HSV2 when administered to a subject.
-
公开(公告)号：WO2022003363A1
公开(公告)日：2022-01-06
申请号：PCT/GB2021/051679
申请日：2021-07-01
发明人： ISALAN, Mark , MIELCAREK, Michal
IPC分类号： C07K14/005 , C12N15/861 , C07K14/47 , A61K38/00 , A61P25/00 , A61K48/005 , C07K14/4702 , C07K2319/02 , C07K2319/10 , C07K2319/715 , C07K2319/73 , C07K2319/81 , C12N2710/16622 , C12N2750/14143
摘要： Disclosed herein are polypeptides for use in treating diseases. Therapeutic uses and methods for treating diseases are also disclosed. Also disclosed is a method and associated peptides and nucleic acids for active, long-term delivery of therapeutic molecules to target cells in vivo or in vitro.
-
公开(公告)号：WO2020243706A1
公开(公告)日：2020-12-03
申请号：PCT/US2020/035558
申请日：2020-06-01
IPC分类号： C12N15/869 , C12N15/85 , C07K14/03 , C12N5/10 , C12N15/864 , A61K48/00 , C07K14/005 , C12N15/86 , C12N2710/16622 , C12N2710/16643 , C12N2710/16644 , C12N2710/16652 , C12N2750/14143 , C12N2750/14152 , C12N2800/22 , C12N2830/50
摘要： The invention described herein provides a recombinant replication-defective virus derived from Herpesvirales order, wherein the virus is characterized by a complete deletion of a gene encoding ICP27, or a functional equivalent gene thereof. The invention also provides production cell lines for such recombinant replication-defective virus, wherein the cell lines have a coding sequence for ICP27 or a functional equivalent thereof, and wherein the coding sequence has no or minimal sequence overlap with the virus characterized by the complete deletion of the gene encoding ICP27. Method of using such recombinant replication-defective virus and production cell lines are also provided.
-
公开(公告)号：WO2023065502A1
公开(公告)日：2023-04-27
申请号：PCT/CN2021/138038
申请日：2021-12-14
申请人： 中国科学院深圳先进技术研究院
IPC分类号： C12N15/49 , C12N5/10 , C12N15/867 , C12N15/65 , C12N7/01 , C07K14/005 , C12N15/86 , C12N2510/02 , C12N2710/16621 , C12N2710/16622 , C12N2710/16652 , C12N2740/15043 , C12N5/0693 , C12N7/00
摘要： 一种重组单纯疱疹病毒的亲和筛选细胞系及其构建方法，包括：构建表达HER2的跨膜区及胞外区HER2CT9基因的慢病毒Ls18；使用慢病毒表达载体pLs18包装所述慢病毒Ls18后感染小鼠黑色素瘤细胞系B16，获得所述亲和筛选细胞系B16-HER2CT9；所述慢病毒表达载体pLs18如序列表中SEQ ID NO.10所示，所述HER2CT9基因如序列表中SEQ ID NO.7所示。基于如上所述的亲和筛选细胞系B16-HER2CT9的应用，还提供了一种单纯疱疹病毒的重组改造方法，通过亲和筛选细胞系B16-HER2CT9选择性地从同源重组后的病毒细胞中筛选出重组单纯疱疹病毒，其工艺更加高效且获得纯度更高的重组单纯疱疹病毒。
-
公开(公告)号：WO2022010277A1
公开(公告)日：2022-01-13
申请号：PCT/KR2021/008693
申请日：2021-07-08
发明人： KONG, Hoon Young , KIM, Jong-Mook , KIM, Jee Yong , SHIN, Sunhwa , LEE, Kyungwon , HAN, Joo Seok
IPC分类号： C12N15/113 , C12N15/86 , A61K39/12 , A61P27/02 , C12N15/85 , C12N2310/11 , C12N2310/113 , C12N2310/141 , C12N2710/16622 , C12N2830/42 , C12N2830/60 , C12N2840/445
摘要： Novel intron fragments are provided. The intron fragments can increase gene expression to levels equal to or higher than those achieved by the full-length intron while maintaining their ability to increase gene expression even when combined with various types of promoters and splicing donors. Particularly, the intron fragments enable loading of larger transgenes when used in genetic information delivery systems whose size is limited, for example, adeno-associated viruses (AAVs) and rhabdoviruses. Therefore, the use of the intron fragments is expected to extend the range of therapeutic genes.
-
公开(公告)号：WO2022006179A1
公开(公告)日：2022-01-06
申请号：PCT/US2021/039717
申请日：2021-06-29
发明人： SCHMIDT, Darby, Rye , NAGARAJAN, Niranjana, Aditi , KAISER, William, Joseph , GOUGH, Peter, Joseph , DHAKAL, Sabin
IPC分类号： C12N7/00 , C12N15/87 , C07K14/005 , C07K14/47 , C07K14/4747 , C07K14/705 , C12N15/86 , C12N2710/16622 , C12N2710/16632 , C12N2710/16643 , C12N2710/24122
摘要： In certain aspects, the disclosure relates to a virus engineered to comprise one or more polynucleotides that promote thanotransmission by a target cell. Thanotransmission is communication between cells that is a result of activation of a cell turnover pathway in a target cell, which signals a responding cell to undergo a biological response. Methods of promoting thanotransmission by a target cell, methods of promoting an immune response in a subject, and methods of treating cancer in a subject are also disclosed.
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.012 秒)
